Fox Run Management L.L.C. Makes New Investment in Immatics N.V. $IMTX

Fox Run Management L.L.C. bought a new stake in Immatics N.V. (NASDAQ:IMTX) during the 2nd quarter, HoldingsChannel reports. The fund bought 25,233 shares of the company’s stock, valued at approximately $136,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. TD Asset Management Inc lifted its holdings in Immatics by 19.5% during the 2nd quarter. TD Asset Management Inc now owns 288,256 shares of the company’s stock worth $1,551,000 after buying an additional 47,010 shares during the period. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Immatics during the second quarter valued at about $237,000. Vontobel Holding Ltd. bought a new position in Immatics in the second quarter worth approximately $59,000. Vestal Point Capital LP lifted its holdings in shares of Immatics by 14.6% in the first quarter. Vestal Point Capital LP now owns 7,192,700 shares of the company’s stock valued at $32,439,000 after purchasing an additional 917,700 shares in the last quarter. Finally, Trexquant Investment LP purchased a new position in Immatics during the first quarter worth about $783,000. Institutional investors own 64.41% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on IMTX shares. Zacks Research raised shares of Immatics from a “strong sell” rating to a “hold” rating in a report on Monday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a research note on Wednesday, October 8th. Mizuho set a $19.00 price objective on shares of Immatics in a research report on Wednesday, October 29th. Finally, Guggenheim started coverage on Immatics in a report on Thursday, September 18th. They set a “buy” rating and a $16.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Immatics Price Performance

IMTX opened at $10.20 on Friday. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -15.69 and a beta of 1.24. Immatics N.V. has a one year low of $3.30 and a one year high of $11.25. The business has a 50 day simple moving average of $8.81 and a two-hundred day simple moving average of $6.75.

Immatics (NASDAQ:IMTX) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.28). Immatics had a negative net margin of 59.29% and a negative return on equity of 15.60%. The company had revenue of $6.48 million during the quarter, compared to the consensus estimate of $13.05 million. As a group, sell-side analysts expect that Immatics N.V. will post -0.72 EPS for the current fiscal year.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.